Thorne is on pace for $650 million in sales as Gen Z fuels a supplement boom — despite subscription fatigue
Estimated Price Impact
Pre vs Post NewsAI Executive Summary
Thorne is projected to achieve $650 million in sales, significantly benefiting from the health-conscious behaviors of Gen Z and millennial consumers. Despite some signs of subscription fatigue among customers, the overall trend in supplement demand remains strong. The company has seen its business more than double from 2022 to 2025, indicating robust growth in the sector. This trend positions Thorne favorably in a competitive market that caters to a younger demographic prioritizing wellness. As supplements gain popularity, other companies in the sector may also experience increased sales and stock movements.
Trader Insight
"Consider investing in Thorne (THRN) to capitalize on the anticipated sales growth and bullish sentiment around the supplement market."